https://ir.kiorapharma.com/news-events/news-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_97e3629f093b7a3eb5d068243dee1637/kiorapharma/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.kiorapharma.com/news-events/news-releases/detail/248/kioras-phase-1-abacus-study-of-kio-301-in-retinitis-pigmentosa-published-in-nature-medicine-phase-2-trial-underway Tue, 14 Apr 26 07:00:00 -0400 https://ir.kiorapharma.com/news-events/news-releases/detail/248/kioras-phase-1-abacus-study-of-kio-301-in-retinitis-pigmentosa-published-in-nature-medicine-phase-2-trial-underway https://ir.kiorapharma.com/news-events/news-releases/detail/247/kiora-pharmaceuticals-announces-private-placement-for-up-to-24-million-led-by-perceptive-advisors Tue, 07 Apr 26 07:00:00 -0400 https://ir.kiorapharma.com/news-events/news-releases/detail/247/kiora-pharmaceuticals-announces-private-placement-for-up-to-24-million-led-by-perceptive-advisors https://ir.kiorapharma.com/news-events/news-releases/detail/246/kiora-pharmaceuticals-announces-management-team-changes Thu, 02 Apr 26 16:30:00 -0400 https://ir.kiorapharma.com/news-events/news-releases/detail/246/kiora-pharmaceuticals-announces-management-team-changes https://ir.kiorapharma.com/news-events/news-releases/detail/245/kiora-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-results-company-advances-retinal-disease-pipeline-with-two-active-phase-2-clinical-trials Wed, 25 Mar 26 07:00:00 -0400 https://ir.kiorapharma.com/news-events/news-releases/detail/245/kiora-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-results-company-advances-retinal-disease-pipeline-with-two-active-phase-2-clinical-trials https://ir.kiorapharma.com/news-events/news-releases/detail/244/kiora-pharmaceuticals-to-present-at-oppenheimers-36th-annual-healthcare-life-sciences-conference Thu, 19 Feb 26 08:30:00 -0500 https://ir.kiorapharma.com/news-events/news-releases/detail/244/kiora-pharmaceuticals-to-present-at-oppenheimers-36th-annual-healthcare-life-sciences-conference https://ir.kiorapharma.com/news-events/news-releases/detail/243/retinal-disease-expert-dr-taiji-sakamoto-joins-kiora-pharmaceuticals-scientific-advisory-board Tue, 27 Jan 26 07:00:00 -0500 https://ir.kiorapharma.com/news-events/news-releases/detail/243/retinal-disease-expert-dr-taiji-sakamoto-joins-kiora-pharmaceuticals-scientific-advisory-board https://ir.kiorapharma.com/news-events/news-releases/detail/242/kiora-pharmaceuticals-granted-u-s-patent-covering-additional-formulations-for-the-kio-100-family-of-anti-inflammatory-compounds Mon, 01 Dec 25 06:45:00 -0500 https://ir.kiorapharma.com/news-events/news-releases/detail/242/kiora-pharmaceuticals-granted-u-s-patent-covering-additional-formulations-for-the-kio-100-family-of-anti-inflammatory-compounds https://ir.kiorapharma.com/news-events/news-releases/detail/241/kiora-pharmaceuticals-reports-third-quarter-2025-results-company-advances-pipeline-with-two-actively-enrolling-phase-2-clinical-trials-for-retinal-diseases Fri, 07 Nov 25 06:00:00 -0500 https://ir.kiorapharma.com/news-events/news-releases/detail/241/kiora-pharmaceuticals-reports-third-quarter-2025-results-company-advances-pipeline-with-two-actively-enrolling-phase-2-clinical-trials-for-retinal-diseases https://ir.kiorapharma.com/news-events/news-releases/detail/240/kiora-pharmaceuticals-joins-rare-x-vision-consortium-promoting-collaboration-and-development-of-new-treatments-for-rare-ocular-disorders Thu, 30 Oct 25 09:00:00 -0400 https://ir.kiorapharma.com/news-events/news-releases/detail/240/kiora-pharmaceuticals-joins-rare-x-vision-consortium-promoting-collaboration-and-development-of-new-treatments-for-rare-ocular-disorders https://ir.kiorapharma.com/news-events/news-releases/detail/239/kiora-pharmaceuticals-to-participate-in-the-2025-maxim-growth-summit-and-eyecelerator-aao-2025 Wed, 15 Oct 25 07:00:00 -0400 https://ir.kiorapharma.com/news-events/news-releases/detail/239/kiora-pharmaceuticals-to-participate-in-the-2025-maxim-growth-summit-and-eyecelerator-aao-2025